Section Arrow
Quote
SLS.NASDAQ
- SELLAS Life Sciences Group
Quotes are at least 15-min delayed:2025/04/12 04:11 EDT
Last
 1.13
+0.02 (+1.80%)
Day High 
1.14 
Prev. Close
1.11 
1-M High
1.28 
Volume 
517.23K 
Bid
1.13
Ask
1.15
Day Low
1.11 
Open
1.12 
1-M Low
0.9516 
Market Cap 
100.84M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 1.08 
20-SMA 1.13 
50-SMA 1.21 
52-W High 1.84 
52-W Low 0.772 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.50/-0.40
Enterprise Value
101.30M
Balance Sheet
Book Value Per Share
0.10
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
RXRXRecursion Pharmaceuticals5.76+1.25+27.72%-- 
THTXTheratechnologies1.94+0.61+45.86%-- 
CDTConduit Pharmaceuticals Inc0.9101-0.1599-14.94%-- 
PRTGPortage Biotech Inc8.59+3.49+68.43%0.17PE
HEPAHepion Pharmaceuticals0.422-0.0091-2.11%-- 
Quotes are at least 15-min delayed：2025/04/12 04:11 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.